Condition: Systemic Lupus Erythematosus · Sponsor: GlaxoSmithKline
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Scottsdale, Arizona, United States | Withdrawn |
| GSK Investigational Site | Aurora, Colorado, United States | Recruiting |
| GSK Investigational Site | Las Vegas, Nevada, United States | Recruiting |
| GSK Investigational Site | Columbus, Ohio, United States | Recruiting |
| GSK Investigational Site | Oklahoma City, Oklahoma, United States | Withdrawn |
| GSK Investigational Site | Dallas, Texas, United States | Withdrawn |
| GSK Investigational Site | Buenos Aires, Argentina | Recruiting |
| GSK Investigational Site | Rosario, Argentina | Recruiting |
| GSK Investigational Site | San Juan Bautista, Argentina | Recruiting |
| GSK Investigational Site | San Miguel de Tucumán, Argentina | Recruiting |
| GSK Investigational Site | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| GSK Investigational Site | Juiz de Fora, Brazil | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06576271